References
- Argyriou A. Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics. 2015;3(2):187-197. http://doi.org/10.3390/toxics3020187
- Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Management and Research. 2014;6:135-147. http://doi.org/10.2147/CMAR.S44261
- Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica. 2007;46(8):1131-1137. http://doi.org/10.1080/02841860701355055
- Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-20. http://doi.org/10.1097/NCC.0b013e31820251de
- Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews. 2008;34(4):368-377. http://doi.org/10.1016/j.ctrv.2008.01.003
- Chaudhary R, Singh B, Kumar M, Gakhar SK, Saini AK, Parmar VS, et al. Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. Drug Metabolism Reviews. 2015;47(3):281-290. http://doi.org/10.3109/03602532.2015.1047027
- Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis. Journal of the Peripheral Nervous System. 2015;20(1):15-23. http://doi.org/10.1111/jns.12110
- Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. The Lancet Oncology. 2011;12(12):1151-1161. http://doi.org/10.1016/s1470-2045(11)70131-0
- Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer. 2013;119(19):3570-3577. http://doi.org/10.1002/cncr.28234
- Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The Pharmacogenomics Journal. 2013;13(5):403-409. http://doi.org/10.1038/tpj.2012.31
- Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study. Annals of Oncology. 2014;25(2):398-403. http://doi.org/10.1093/annonc/mdt546
- Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemotherapy and Pharmacology. 2011;67(5):1179-1187. http://doi.org/10.1007/s00280-010-1466-y
- Sereno M, Gutierrez-Gutierrez G, Rubio JM, Apellaniz-Ruiz M, Sanchez-Barroso L, Casado E, et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17(1):63. http://doi.org/10.1186/s12885-016-3031-5
- Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clincal Cancer Research. 2006;12(10):3050-3056. http://doi.org/10.1158/1078-0432.ccr-05-2076
- Cortejoso L, Garcia MI, Garcia-Alfonso P, Gonzalez-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology. 2013;71(6):1463-1472. http://doi.org/10.1007/s00280-013-2145-6
- Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-2836. http://doi.org/10.1002/cncr.26614
- Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemotherapy and Pharmacology. 2011;67(6):1323-1331. http://doi.org/10.1007/s00280-010-1425-7
- McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology. 2010;28(20):3227-3233. http://doi.org/10.1200/jco.2009.21.7943
- Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology. 2010;17(7):963-968. http://doi.org/10.1111/j.1468-1331.2010.02966.x
- Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, et al. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research. 2007;13(21):6359-6368. http://doi.org/10.1158/1078-0432.ccr-07-0660
- Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. International Journal of Clinical Pharmacology and Therapeutics. 2013;51(6):475-481. http://doi.org/10.5414/CP201851
- Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. International Journal of Clinical Pharmacology and Therapheutics. 2010;48(11):729-734. https://doi.org/10.5414/CPP48729
- Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of Oncology. 2016;27(6):1143-1148. http://doi.org/10.1093/annonc/mdw074
- Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2009;100(7):1261-1266. http://doi.org/10.1111/j.1349-7006.2009.01186.x
- Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis. British Journal of Cancer. 2010;102(6):987-994. http://doi.org/10.1038/sj.bjc.6605595
- Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. Journal of Clinical Oncology. 2009;27(33):5519-5528. http://doi.org/10.1200/jco.2008.21.6283
- Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British Journal of Cancer. 2008;99(7):1050-1055. http://doi.org/10.1038/sj.bjc.6604671
- Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Journal of the National Cancer Institute. 2002;94(12):936-942. https://doi.org/10.1093/jnci/94.12.936
- Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters. 2013;6(3):648-654. http://doi.org/10.3892/ol.2013.1467
- Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of Clinical Oncology. 2007; 25(10):1247-1254. http://doi.org/10.1200/jco.2006.08.1844
- Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2010;101(2):530-535. http://doi.org/10.1111/j.1349-7006.2009.01418.x
- Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology. 2010;28(15):2556-2564. http://doi.org/10.1200/jco.2009.25.2106
- Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3-4):254-256. http://doi.org/ 10.1159/000236049
- Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology. 2013;71(4):843-851. http://doi.org/10.1007/s00280-013-2075-3
- Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer epidemiology. 2010;34(2):189-193. http://doi.org/10.1016/j.canep.2010.02.008
- Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(Suppl 4):iv45-54. http://doi.org/10.1093/neuonc/nos203
- Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. Journal of National Comprehensive Cancer Network. 2009;7(Suppl 5):S1-S26.
- Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology. 2006;24(14): 2158-2163. http://doi.org/10.1200/jco.2006.06.5961
- Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research. 2005;11(16):5878-5885. http://doi.org/10.1158/1078-0432.CCR-04-2618
- Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, et al. Associations between UGT1A1* 6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemotherapy and Pharmacology. 2014;73(4):779-788. http://doi.org/10.1007/s00280-014-2405-0
- Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, et al. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced nonsmall cell lung cancer. Cancer Chemotherapy and Pharmacology. 2009;64(5):917-924. http://doi.org/10.1007/s00280-009-0943-7
- Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-Cancer Drugs. 2013;24(10):1069-1078. http://doi.org/10.1097/CAD.0000000000000002
- Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: Chemotherapy-induced peripheral neuropathy. Methods in Molecular Biololgy Pharmacogenomics in Drug Discovery and Development. 2014;1175:301-322. http://doi.org/10.1007/978-1-4939-0956-8_12